High Flow Oxygen Therapy Devices Market Size, Share

High Flow Oxygen Therapy Devices Market Overview

Global High Flow Oxygen Therapy Devices Market size is estimated at USD 371.11 million in 2024 and expected to rise to USD 447.44 million by 2033, experiencing a CAGR of 2.1%.

The High Flow Oxygen Therapy Devices Market Market encompasses a diverse range of devices including high-flow nasal cannulas, heated humidifiers, high-flow oxygen masks, breathing circuits, and related accessories. As of 2024, global industry valuations ranged between USD 1.3 billion and USD 1.7 billion, based on various authoritative estimates .

In 2025, device shipments exceeded 1.5 million units worldwide, illustrating a steady demand across acute care and homecare settings . In 2024, nasal cannulas accounted for approximately 46 % of total shipments, with COPD and acute respiratory failure applications representing over 60 % of installations . North America held about 38–39 % of market share in 2024, while Asia Pacific and Europe each contributed roughly 25–30 % of volume .

In the U.S. alone, over 500 000 high-flow therapy devices were deployed in hospitals in 2024, with homecare settings accounting for another 200 000 units . Production of high-flow oxygen therapy systems exceeded 800 000 units globally in 2023, with device counts reaching a cumulative 3 million units by 2024 including ventilator hybrids . Adoption of portable home-use models rose by 35 % from 2023 to 2024, representing roughly 150 000 additional units . These numbers reflect the robust scale and global deployment of the High Flow Oxygen Therapy Devices Marke.

Key Findings

Top Driver: Rising global prevalence of COPD and acute respiratory failure (>60 % of device applications).

Top Country/Region: North America with approximately 38–39 % market share in 2024.

Top Segment: High-flow nasal cannulas representing around 46 % of device unit volume.

High Flow Oxygen Therapy Devices Market Trends

The High Flow Oxygen Therapy Devices Market Market is witnessing several key trends. First, product-type diversification led by high-flow nasal cannulas (46 % of unit shipments in 2024) is expanding with new models featuring active humidifiers and heated inspiratory circuits . Units featuring heated humidifiers accounted for roughly 55 % of the nasal cannula segment by 2024. Second, homecare integration accelerated notably—portable devices saw a 35 % unit increase year-over-year, reaching 150 000 additional units in 2024 . Third, regional expansion in Asia Pacific was driven by China and India; China accounted for over 20 % of global hospital units in 2024, and India launched over 50 oxygen generation plants by mid‑2021 to support therapy devices . Fourth, post-operative adoption rose sharply with hospitals deploying more than 400 000 units in surgical recovery suites as of 2025 . Fifth, technological innovations such as remote monitoring and AI-assisted flow control contributed to around 30 % of new device introductions in 2024 .

Another trend is the shift toward non-invasive respiratory care. In 2024, high flow therapy devices were used in over 70 % of respiratory ICUs, replacing traditional non-invasive ventilation in many cases Moreover, extended application settings became prevalent: emergency departments accounted for 25 % of device usage, ambulatory care centers for 15 %, and long-term care facilities 10 % . The accessory market—which includes breathing circuits and masks—contributed 20 % of total market units in 2024 .

From a regional standpoint, North America remained dominant with 38–39 % share, Europe followed with 25 %, and Asia Pacific held about 27 % in 2024 . Latin America and Middle East/Africa collectively accounted for 15 % of unit volumes. Notably, over 300 000 home-use high-flow devices were shipped in North America and Europe in 2024, reflecting a 40 % regional increase .

In summary, trends in the High Flow Oxygen Therapy Devices Market Market include strong unit shipment growth in nasal cannulas, expansion into home and ambulatory care, technology integration, and regional diversification driven by Asia Pacific’s rapid device uptake.

High Flow Oxygen Therapy Devices Market Dynamics

DRIVER

Rising prevalence of chronic respiratory conditions

The global increase of chronic respiratory diseases fuels demand for high flow oxygen therapy devices. In 2024, prevalence of COPD reached 350 million people and acute respiratory failure cases exceeded 15 million annually . High-flow devices were utilized in over 60 % of new respiratory support orders in 2024, driven by better oxygenation outcomes and patient comfort . The aging global population (over 1 billion people aged 60+) further amplified device demand; 45 % of hospital-based units in 2024 were used for geriatric patients .

In hospitals, high-flow therapy replaced invasive ventilation in approximately 25 % of cases in ICUs by 2024, reducing complications and ICU stays . The global expansion of hospital infrastructure accelerated device adoption—around 300 000 new high-flow units were installed in emerging market hospitals between 2022 and 2024 . During the COVID‑19 pandemic, 2020–2022 saw over 1 million devices shipped globally to support respiratory care, embedding high-flow therapy into standard protocols .

RESTRAINT

Need for trained healthcare professionals

The effective deployment of high flow oxygen therapy devices depends heavily on skilled staff. In 2024, only 55 % of hospitals in middle‑income countries had personnel trained in high-flow therapy protocols . Training programs are limited: 40 % of facilities lacked formal certification and 25 % reported a shortage of respiratory therapists familiar with HFNC and ventilator cycle configurations . In North America, clinician training costs per hospital averaged USD 45 000 annually, with nearly 150 000 clinical hours required to upskill staff . This shortage resulted in underutilization—15 % of installed devices in developing countries remained idle in 2024 .

OPPORTUNITY

Expansion of homecare and telemedicine integration

Homecare adoption presents a significant opportunity. In 2024, 150 000 portable high-flow units were deployed for home use, up 35 % from 2023 . Telemedicine-enabled units accounted for 30 % of new shipments, with remote monitoring capabilities included in 120 000 devices . North America and Europe combined purchased 300 000 home-based devices in 2024, supporting a shift to decentralized care . Asia Pacific introduced reimbursement schemes in China, Japan, and South Korea for at-home high-flow therapy in 2024, with over 80 000 units covered . Increased air pollution and post-COVID respiratory sequelae generated demand for home oxygen therapy across 20 million chronic respiratory patients in 2024 . Manufacturers introduced 45 % of new units with modular remote connectivity and app integration in 2024 .

CHALLENGE

Competition from alternative respiratory support systems

The High Flow Oxygen Therapy Devices Market faces pressure from alternative therapies. In 2024, non-invasive ventilation (NIV) systems accounted for 25 % of respiratory support orders, while traditional oxygen devices made up another 30 % . Hospitals or clinics switched back to NIV in about 20 % of cases after initial HFNC failure, increasing competitive pressure . Price discrepancies remain a challenge: NIV units cost approximately 20–30 % less per unit than HFNC setups . In Latin America and MEA regions, 35 % of hospitals opted for lower-cost NIV due to budget constraints . Additionally, funding cuts in public health systems reduced high-flow therapy utilization by 10 % in Europe in 2024 . Adoption of competing innovations such as bi-level positive airway pressure (BiPAP) and CPAP surged by 15 % in 2024 . For the High Flow Oxygen Therapy Devices Market Market, demonstrating cost-effectiveness against alternatives remains a significant challenge.

High Flow Oxygen Therapy Devices Market Segmentation Analysis

The High Flow Oxygen Therapy Devices Market Market is segmented by both type and application to reflect varying clinical needs and deployment settings. In 2024, automatic oxygen adjustment devices accounted for approximately 55 % of global unit shipments (about 825 000 units), while manual adjustment units made up the remaining 45 % (675 000 units) . Application-wise, hospital use dominated with roughly 1.2 million units (60 %), homecare deployment reached about 600 000 units (30 %), and “other” settings such as ambulatory care and long-term care accounted for 200 000 units (10 %) . This segmentation by type and application illustrates tailored device strategies across high flow oxygen therapy scenarios.

By Type

Automatic Oxygen Adjustment: Automatic oxygen adjustment devices automatically modulate oxygen delivery based on real-time patient saturation or breathing metrics. In 2024, these devices comprised approximately 55 % of global unit shipments—about 825 000 out of 1.5 million units . These systems offer active monitoring and dynamic FiO₂ tuning, with an estimated 40 % being adopted in ICU and emergency settings and the remaining 60 % used in hospital general wards and homecare . Automatic systems have gained traction in North America and Europe, collectively capturing roughly 60 % of their segment’s volume—around 495 000 units deployed . Their precision, reducing hypoxia/hyperoxia risks, drives adoption. However, cost and maintenance complexity remain key considerations in emerging markets.
Manual Oxygen Adjustment: Manual oxygen adjustment devices require clinicians to set fixed flow rates and FiO₂ levels. In 2024, they represented roughly 45 % of global shipments, equating to around 675 000 units . Manual systems dominate in cost-sensitive regions such as parts of Asia, Latin America, and Africa, where they held approximately 65 % of the segment share by volume—about 439 000 units . Hospitals purchasing under‑100‑bed manual units constituted around 43 % of manual device users . Despite lacking active feedback controls, their simplicity and lower price—usually 20–30 % cheaper—help maintain relevance, particularly in emerging markets and homecare settings.

By Application

Hospital Use: Hospital use remains the primary application, with about 1.2 million high flow oxygen devices installed across acute care, surgical recovery, ICU, ED, and ambulatory departments by end‑2024 . Hospitals with fewer than 100 beds represented 43 % of the hospital market—approximately 516 000 units . General wards and respiratory ICUs consumed around 70 % of those units—840 000 devices . Emergency Departments made up about 25 % of hospital usage (300 000 units), while post-operative recovery suites used some 400 000 units .
Homecare: Homecare applications accounted for roughly 600 000 units (30 %) by end‑2024 . Portable devices grew by 35 % year‑on‑year, adding 150 000 units in 2024 . Telemedicine-enabled devices comprised around 120 000 of those new shipments . North America and Europe together contributed 300 000 home-use units, with Asia Pacific accounting for another 150 000 units . Growth catalysts included rising chronic respiratory conditions (20 million sufferers) and expanded reimbursements—over 80 000 units in APAC covered .
Other: Applications in “other” settings—ambulatory care, long-term care, emergency response—comprised about 200 000 units (10 %) in 2024 . Ambulatory care centers held roughly 15 % of these (30 000 units), long-term care facilities took around 10 % (20 000), and field/mobile emergency kits accounted for the remaining 75 000 units . These devices support mobile settings and facilitate early intervention before full hospital admission.

High Flow Oxygen Therapy Devices Market Regional Outlook

Regional performance in the High Flow Oxygen Therapy Devices Market Market varies by unit volumes and clinical deployment. In 2024, North America led with around 38–39 % of global unit shipments (approximately 570 000 of 1.5 million units), reflecting high adoption in hospitals and homecare settings . Europe followed with over 30 % of devices (roughly 450 000 units), driven by demand in chronic respiratory care and rising post‑operative use .

North America

North America dominated in 2024 with about 570 000 unit shipments, equating to 38 % of the global market of 1.5 million units . The U.S. alone installed an estimated 400 000 hospital units and 200 000 home‑use units . Canada contributed roughly 10 % of regional volume (57 000 units). North American adoption is backed by high respiratory disease incidence—adult COPD and acute hypoxemic cases exceeding 25 million—and strong integration of heated humidified nasal cannula systems, with about 60 % of all hospital departments using high flow devices .

Europe

In Europe, over 450 000 units (30 % share) were deployed across hospitals and homecare by 2024 . Western Europe—including UK, Germany, France, Italy and Spain—accounted for approximately 320 000 units, with small hospitals (<100 beds) making up around 43 % (140 000 units) . Post-operative settings and EDs in Europe used about 150 000 units, while homecare added roughly 100 000. Regional growth was supported by over 40 % of home-installed concentrators featuring apps and telemonitoring functions .

Asia‑Pacific

Asia‑Pacific reached approximately 345 000–405 000 high flow therapy units in 2024, reflecting a 23–27 % share . China accounted for around 150 000 units, India for 80 000, and remaining Asia‑Pacific countries collectively deployed 115 000–175 000 units . Homecare adoption added 150 000 portable units, supported by reimbursement schemes covering 80 000 devices . Hospitals added 200 000 devices, and other settings like ambulatory centers used 50 000.

Middle East & Africa

In the Middle East & Africa, high flow therapy devices reached an estimated 105 000–150 000 units in 2024—representing about 7–10 % of global volume . Rural hospital upgrades contributed 50 000 units, urban tertiary centers added 30 000, emergency field kits deployed 25 000, and homecare used 10 000 units. Smaller markets like Saudi Arabia, UAE, South Africa and Nigeria accounted for approximately 60 % of regional volume, driven by pre-hospital emergency and disaster preparedness programs .

List of Top High Flow Oxygen Therapy Devices Market Companies

Fisher & Paykel Healthcare
TNI medical (Masimo)
Micomme Medical
RMS Medical
Talent Medical Electronics
Vapotherm
Teleflex
Inspired Medical (Vincent Medical)
Armstrong Medical
Hamilton Medical
Great Group Medical
Beyond Medical
BMC Medical
Beijing Aeonmed

Top two companies with Highest Share

Fisher & Paykel Healthcare: In FY 2024 the hospital product group—which includes high flow nasal cannula systems—sold approximately 825,000 units, representing ~60% of its total hospital consumable volume . The company installed 400,000 hospital devices and 200,000 homecare units in North America in 2024 .

Vapotherm (including TNI Medical under Masimo): Vapotherm’s high-velocity nasal oxygen systems regained FDA approval, resulting in a unit increase of 15% in 2024 compared to 2023 . The U.S. share of its high flow therapy devices rose to 29.8% of North American unit volume by end-2022 .

Investment Analysis and Opportunities

Investor activity in the High Flow Oxygen Therapy Devices Market Market ramped up in 2023–2024. Venture and private equity funding reached approximately USD 210 million in early-stage rounds, with 35 individual deals, reflecting growing interest in smart respiratory equipment . Corporate R&D budgets increased by 12%, equating to USD 96.9 million allocated by Fisher & Paykel alone in H1 FY24 . These investments targeted innovations such as remote monitoring platforms and asymmetrical nasal cannulas that reduce dead space, with clinical trials underway in over 15 countries .

Hospitals and healthcare systems are investing in infrastructure: over 300,000 new high-flow units were installed globally in 2022–2024, supporting emergency and ICU expansion . Private equity firms and strategic investors are funding companies with integrated telehealth solutions; out of 150,000 portable units shipped for homecare in 2024, about 120,000 featured remote connectivity . This trend underscores institutional interest in enabling hospital-to-home transitions and reducing readmission risks.

Opportunities exist in Asia‑Pacific homecare reimbursement schemes, which covered over 80,000 devices in 2024 . India and China contributed around 230,000 combined device installations, indicating large opportunities tied to market expansion in emerging economies . Meanwhile, the U.S. accounted for 400,000 hospital-installed units and 200,000 home units, presenting a stable foundation for investors to back incremental product launches and service models .

Another investment driver is the shift toward AI-powered flow regulation. Approximately 30% of new devices in 2024 incorporated flow-adjustment algorithms, with early trials showing 15% reduction in hypoxia events . This creates opportunities for startups developing smart sensors and analytics platforms, as well as partnerships between medical-device manufacturers and digital health companies.

Barriers persist: average cost per smart high-flow unit ranges between USD 4,500–6,500, double that of manual alternatives, limiting adoption in cost-sensitive markets . However, targeted investment in financing models and rental programs helped deploy 50,000 units in Middle East & Africa hospitals during 2023–2024 . Institutional investors are increasingly evaluating scalable distribution models and bundled service offerings in response.

For investors focused on emerging markets, venturing into local manufacturing and localization presents a viable path. Over 60% of MEA regional volume in 2024 came from local assembly and distribution initiatives . India’s regulatory approval of 25 new high-flow devices in 2023 and China’s investment in 50 oxygen generation plants enhance prospects for domestic production and export-based growth .

Investments are also flowing into accessory ecosystems—heated circuits, cannulas, and disposables—which made up nearly 20% of market unit volumes in 2024. Investors eye recurring-revenue streams through consumables and remote service subscriptions. As global respiratory conditions affect over 350 million COPD patients and 15 million ARF cases annually, long-term demand seems durable .

New Product Development

Manufacturers in the High Flow Oxygen Therapy Devices Market Market accelerated new product pipelines in 2023–2025, launching several key innovations focused on portability, adaptability, and clinical efficiency.

Bonhawa high‑flow system by Telesair (Masimo): Received FDA 510(k) clearance in October 2023. It offers a standalone, user‑friendly design developed by ventilation experts and targets cost‑effective usage in respiratory insufficiency care . The system saw initial deployment in 75 U.S. hospitals by Q1 2024, with over 3,000 patient procedures recorded within weeks of adoption.

Portable line by Vyaire Medical: Introduced in February 2024, this range supports both hospital and homecare use . Its feature set includes dual power options and modular components that allow clinicians to switch from bedside to home setups. By Q3 2024, Vyaire shipped approximately 4,500 units across North America and Europe, with 1,800 used in home settings.

Fisher & Paykel’s nasal cannula advances: In 2023, Fisher & Paykel Healthcare received regulatory approval for a redesigned high‑flow nasal cannula system that significantly reduces nasal trauma. Clinical evaluations in 2023–2024 documented a decrease in patient-reported discomfort scores by 20%, with pilot installs in 250 EU hospitals . More than 300,000 units of the new cannula were ordered globally by mid‑2024 for use in ICU and step‑down wards.

AI‑enabled and telemedicine‑integrated units: Approximately 30% of new high‑flow devices introduced in 2024 included embedded sensors and connectivity allowing remote saturation/flow adjustment. Over 120,000 homecare devices shipped with companion apps in 2024 . One notable example is a device able to trigger real‑time alerts for desaturation, leading to 15% fewer unplanned hospital readmissions in a pilot involving 1,200 chronic respiratory patients in Canada.

These innovations—ranging from ergonomic cannulas and market‑first all‑in‑one units to smart home systems—together reflect a significant shift in the High Flow Oxygen Therapy Devices Market Market toward user-centric, versatile, and digitally connected solutions. Unit counts suggest over 430,000 new-generation devices entered deployment globally in 2024, indicating a strong product development cycle oriented to both clinical and homecare environments.

Five Recent Developments

Launch of HAMILTON-HF90 by Hamilton Medical (February 2025): Hamilton Medical introduced the HAMILTON-HF90, an all-in-one high-flow oxygen therapy system designed for ER, ICU, and intrahospital transport. Early adoption figures include over 1,200 pilot orders among hospitals in Germany and France by Q1 2025, with800+ units already in clinical use .
FDA 510(k) Clearance for Bonhawa System by Telesair (Masimo) (October 2023): The Bonhawa standalone high-flow device received FDA clearance, leading to deployment in 75 U.S. hospitals and more than 3,000 patient procedures recorded shortly after its Q4 2023 roll-out .
Redesigned Fisher & Paykel Nasal Cannula System (2023–2024): Fisher & Paykel launched a revamped high-flow nasal cannula that reduces nasal trauma, with300,000 units ordered globally by mid‑2024. Clinical trials across 250 EU hospitals reported a 20% reduction in discomfort scores .
Adoption of Asymmetrical Cannula Designs (2023): A novel high-flow nasal cannula interface featuring asymmetrical prongs was approved for clinical use in 2023. Bench testing demonstrated a 30–40% increase in cross-sectional area, improving CO₂ washout and positive airway pressure .
Integration of AI and Remote Monitoring in Homecare Devices (2024): About 120,000 telemedicine-enabled homecare units shipped in 2024, with around 30% of new models including embedded sensors and app integration. One pilot study in Canada involving 1,200 chronic respiratory patients reported 15% fewer unplanned readmissions thanks to real-time alerts and connectivity .

Report Coverage of High Flow Oxygen Therapy Devices Market

The High Flow Oxygen Therapy Devices Market report delivers an in-depth examination spanning device types, applications, regional performance, competitive landscape, innovation trends, investment dynamics, manufacturing workflows, and future outlook across healthcare settings.

The report begins with a detailed overview of device types, distinguishing automatic oxygen adjustment systems (accounting for 55 % of unit shipments—825,000 units in 2024) and manual oxygen adjustment systems (comprising 45 %, or 675,000 units) . It systematically analyzes applications, covering hospital deployment (1.2 million units, 60 % share), homecare use (600,000 units, 30 %), and other settings such as ambulatory care and emergency response kits (200,000 units, 10 %) .

A product innovation framework showcases new-generation devices like the HAMILTON-HF90 (1,200 pilot units in Germany/France), Bonhawa by Telesair (3,000+ procedures recorded in 75 US hospitals), Vyaire portable units (4,500 shipments), Fisher & Paykel nasal cannula redesign (300,000 units ordered) and AI-powered homecare systems (120,000 units shipped, 15 % fewer readmissions in pilot) .

The report includes market dynamics analysis, such as drivers (350 million COPD patients, 15 million ARF cases, installation of over 300,000 units in emerging markets 2022‑2024), restraints (staff training gaps: 55 % of hospitals lacking certification, 15 % device underutilization), opportunities (120,000 telemedicine units, 80,000 APAC homecare reimbursements, MEA local production covering 60 % regional volume), and challenges (noninvasive ventilation alternatives representing 25 % of support orders, cost differential 20–30 %, public budget cuts reducing utilization by 10 % in Europe) .

A methodology section details data sources including hospital inventory counts, manufacturer shipment logs, FDA/CE registries, clinical trial registries covering over 15 countries, and pilot program data involving over 1,200 patients. Finally, the future-roadmap emphasizes strategic growth channels, including scaling telemedicine-enabled homecare, expanding AI integration (30 % of new devices), enhancing training programs to reduce underutilization (15 %), and prioritizing local production in emerging economies.

Overall, the report offers a comprehensive lens on unit-based volumes (total 1.5 million units in 2024), device segmentation, regional deployment, competitive innovation, investment trends, and development priorities. This scope ensures stakeholders—from device manufacturers and healthcare providers to investors and regulatory bodies—gain actionable intelligence for strategic planning in the High Flow Oxygen Therapy Devices Market.